Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy.

Jacqui T NimmoAjay VermaJean-Cosme DodartChang Yi WangJimmy SavistchenkoRonald MelkiRoxana O CarareJames A R Nicoll

Published in: Alzheimer's research & therapy (2020)

These vaccines induce antibodies that bind α-Syn oligomers and aggregates in the human brain and specifically support the choice of the vaccine generating IGG-3 (i.e. UB-312) as a candidate for clinical trials for synucleinopathies.

Keyphrases

clinical trial
phase ii
decision making
risk assessment
study protocol